NBS Technology Uses...
High throughput screens to identify mathematically
synergistic combinations
Genomic & bioinformatic analyses to elucidate novel mechanisms of action
Proprietary
nanochemistry to create new chemical entities
A strategy to rapidly vet new drug entities in disease specific contexts
How We Optimize Efficient Drug Discovery & Development
Nouveau Leverages a Proprietary Platform to Create Unlimited Novel Drug Entities with Superior Pharmacology, Tolerability & Efficacy
Discovery Stage
The discovery stage is predicated on the identification of mathematical and biological drug:drug synergy guided by bioinformatic analyses in a highly disease specific context. We use robotic high through put (HTP) screening in a disease specific manner to identify synergistic drugs.
There are two steps to this. First, by conducting a HTP in a disease which has an unmet medical need and a regulatory need. Second, we start with a "cornerstone" drug that oncologists deem to be critical to treatment of such disease.
This stage also includes in vitro genetic screening to identified combinatorial drug candidates, providing high-value validation of the selection with the goal of derisking before further development.
Synthesis Stage
The Synthesis Stage couples the output from the Discovery Stage with a proprietary nanochemistry platform that produces new drugs in months, not years. The shortened time-frame allows efficient capitalization of the asset.
Clinical Stage
Our clinical candidates are identified based on strong scientific rationale and bioinformatic analysis gathered from the Discovery Stage. Our lead anticancer drugs produced from the Synthesis Stage are tailored to optimize pharmacologic features, tolerability and efficacy. The strategy affords efficient and economical "go-no-go" decision making.